Michael T Chang1, Sunhee Song1,2, Peter H Hwang1. 1. Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A. 2. Department of Otolaryngology-Head & Neck Surgery, Daegu Veterans Hospital, Daegu, Republic of Korea.
Abstract
OBJECTIVE: To assess the efficacy and safety of cryoablation of the posterior nasal nerve (PNN) for treatment of chronic rhinitis. METHODS: This was a prospective single-arm trial of 98 adult patients at six U.S. centers with chronic allergic and nonallergic rhinitis. PNN cryoablation was performed in-office under local anesthesia using a handheld device. Patients discontinued use of intranasal ipratropium 3 days prior to treatment and throughout the study period. Reflective Total Nasal Symptom Score (rTNSS) was measured at pretreatment baseline and posttreatment at 1 month, 3 months, 6 months, and 9 months. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was completed at pretreatment and 3 months posttreatment. Adverse effects and postprocedure medication usage were recorded. RESULTS: Ninety-eight procedures (100%) were successfully completed. rTNSS significantly improved over pretreatment baseline (6.1 ± 1.9) at 1 month (2.9 ± 1.9, P < 0.001), 3 months (3.0 ± 2.3, P < 0.001), 6 months (3.0 ± 2.1, P < 0.001), and 9 months (3.0 ± 2.4, P < 0.001) postprocedure. Nasal congestion and rhinorrhea subscores improved significantly at all time points (P < 0.001). Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups. RQLQ significantly improved over pretreatment baseline (3.0 ± 1.0) at 3 months (1.5 ± 1.0, P < 0.001), and all RQLQ subdomains demonstrated improvement. Of 54 patients using intranasal medication at baseline, 19 (35.2%) were able to discontinue use. Twenty-nine adverse effects were reported, including headache, epistaxis, and sinusitis. CONCLUSION: Cryoablation of the PNN for chronic rhinitis is safe and can result in relief of nasal symptoms and improvements in quality of life. LEVEL OF EVIDENCE: 4 Laryngoscope, 2019.
OBJECTIVE: To assess the efficacy and safety of cryoablation of the posterior nasal nerve (PNN) for treatment of chronic rhinitis. METHODS: This was a prospective single-arm trial of 98 adult patients at six U.S. centers with chronic allergic and nonallergic rhinitis. PNN cryoablation was performed in-office under local anesthesia using a handheld device. Patients discontinued use of intranasal ipratropium 3 days prior to treatment and throughout the study period. Reflective Total Nasal Symptom Score (rTNSS) was measured at pretreatment baseline and posttreatment at 1 month, 3 months, 6 months, and 9 months. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was completed at pretreatment and 3 months posttreatment. Adverse effects and postprocedure medication usage were recorded. RESULTS: Ninety-eight procedures (100%) were successfully completed. rTNSS significantly improved over pretreatment baseline (6.1 ± 1.9) at 1 month (2.9 ± 1.9, P < 0.001), 3 months (3.0 ± 2.3, P < 0.001), 6 months (3.0 ± 2.1, P < 0.001), and 9 months (3.0 ± 2.4, P < 0.001) postprocedure. Nasal congestion and rhinorrhea subscores improved significantly at all time points (P < 0.001). Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups. RQLQ significantly improved over pretreatment baseline (3.0 ± 1.0) at 3 months (1.5 ± 1.0, P < 0.001), and all RQLQ subdomains demonstrated improvement. Of 54 patients using intranasal medication at baseline, 19 (35.2%) were able to discontinue use. Twenty-nine adverse effects were reported, including headache, epistaxis, and sinusitis. CONCLUSION: Cryoablation of the PNN for chronic rhinitis is safe and can result in relief of nasal symptoms and improvements in quality of life. LEVEL OF EVIDENCE: 4 Laryngoscope, 2019.
Authors: Dale Ehmer; Chad M McDuffie; J Bradley McIntyre; Bryan M Davis; Neelesh H Mehendale; John H Willis; Jeremy P Watkins; V Vasu Kakarlapudi Journal: Allergy Rhinol (Providence) Date: 2022-05-29
Authors: J Pablo Stolovitzky; Randall A Ow; Stacey L Silvers; Nadim B Bikhazi; Curtis D Johnson; Masayoshi Takashima Journal: OTO Open Date: 2021-09-10
Authors: Jivianne T Lee; Gregory M Abbas; Daniel D Charous; Pd Dr Med Mandy Cuevas; Prof Dr Med Önder Göktas; Patricia A Loftus; Nathan E Nachlas; Elina M Toskala; Jeremy P Watkins; Prof Dr Med Detlef Brehmer Journal: Am J Rhinol Allergy Date: 2022-07-11 Impact factor: 2.300
Authors: Farrukh R Virani; Machelle D Wilson; Angela M Beliveau; Amarbir S Gill; E Bradley Strong; Toby O Steele Journal: Ear Nose Throat J Date: 2021-06-15 Impact factor: 1.697
Authors: Dale Ehmer; Chad M McDuffie; W Cooper Scurry; J Bradley McIntyre; Neelesh H Mehendale; John H Willis; Ronald B Shealy; Jeremy P Watkins; V Vasu Kakarlapudi Journal: Am J Rhinol Allergy Date: 2021-08-12 Impact factor: 2.467
Authors: Anthony G Del Signore; Joshua B Greene; Joseph L Russell; David M Yen; Ellen M O'Malley; Rodney J Schlosser Journal: Int Forum Allergy Rhinol Date: 2021-08-06 Impact factor: 5.426